Early Data for HER2 Breast Ca Vax Promising
SAN FRANCISCO (MedPage Today) -- A cancer vaccine derived from HER2 protein demonstrated safety and preliminary evidence of activity in a randomized trial of patients with breast cancer. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 10, 2014 Category: Geriatrics Source Type: news

'Got It Right': Guidelines for HER2-Negative Breast Cancer'Got It Right': Guidelines for HER2-Negative Breast Cancer
Dr. Kathy Miller says the ASCO guidelines for advanced HER2-negative breast cancer 'got it right,' focusing on HT, sequential chemo agents, and decisions made jointly by doctors and patients. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 5, 2014 Category: Science Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
(University of Texas M. D. Anderson Cancer Center) A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2014 Category: Cancer & Oncology Source Type: news

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 5, 2014 Category: Cancer & Oncology Source Type: news

ASCO Issues HER2-Negative Breast Cancer Guide
(MedPage Today) -- Hormonal therapy and sequential chemotherapy form the basis of systemic treatment for advanced HER2-negative breast cancer, according to a new clinical guideline. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 3, 2014 Category: Geriatrics Source Type: news

New ASCO Guideline for HER2-negative Advanced Breast CancerNew ASCO Guideline for HER2-negative Advanced Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued a new guideline for the treatment of patients with HER2-negative advanced breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Guidelines for HER2-Negative Advanced Breast Cancer (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology has … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 3, 2014 Category: Primary Care Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - September 3, 2014 Category: Cancer & Oncology Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, News, Source Type: news

New Guidelines for Treating Form of Advanced Breast Cancer
Four-fifths of advanced cases are HER2-negative tumors, doctors' group says Source: HealthDay Related MedlinePlus Page: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 2, 2014 Category: Consumer Health News Source Type: news

Merrimack begins Phase II HERMIONE trial of MM-302 for breast cancer treatment
US-based Merrimack Pharmaceuticals has started the Phase II HERMIONE trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin) to treat patients with HER2-positive locally advanced or met… (Source: Drug Development Technology)
Source: Drug Development Technology - August 12, 2014 Category: Pharmaceuticals Source Type: news

New immunotherapy approach targets HER2-positive breast cancer
A new technique aimed at harnessing the body’s immune system to attack one of the deadliest forms of breast cancer is being developed by British scientists. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - July 31, 2014 Category: Nursing Source Type: news

What Is HER2 Status and How Does It Relate to...
HER2, which is also called HER2/neu, and HER-2, is the acronym for human epidermal growth factor receptor 2. Knowing your HER2 status is an important part of your diagnosis. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - July 20, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

T-DM1 Storms All Stages of HER2+ Breast CancerT-DM1 Storms All Stages of HER2+ Breast Cancer
Dr. Lidia Schapira discusses the TH3RESA trial and how T-DM1 is strongly active across all stages of HER2-positive breast cancer, offering yet another effective option with low toxicity. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Aggressive breast cancer protein discovered
Conclusion This is a valuable laboratory study that furthers our understanding of the way HER2 may promote the growth, proliferation and spread of breast cancer cells, possibly through the influence of the protein integrin αvβ6. The researchers suggest up to 40% of people with HER2-positive breast cancers may also have a high expression of integrin αvβ6. The discovery that integrin αvβ6 may play a role in mediating the growth and progression of these cancers hopefully opens up new treatment possibilities for people with HER2-positive cancers. As the researchers suggest, their study supports...
Source: NHS News Feed - July 7, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Discovery offers treatment hope for HER2 positive breast cancer
The discovery of a molecule that helps a particularly dangerous form of breast tumour grow and spread could lead to new treatments, suggest UK researchers. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - July 4, 2014 Category: Nursing Source Type: news

New treatment to stop spread of breast cancer
The discovery offers hope for 4,000 women diagnosed per year with HER2-positive breast cancer, who do not respond well to the current treatment, Herceptin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 4, 2014 Category: Consumer Health News Source Type: news

T-DM1 Now Preferred for Progressive HER2 Breast CancerT-DM1 Now Preferred for Progressive HER2 Breast Cancer
T-DM1, a successor to trastuzumab, should be the preferred choice for HER2-positive breast cancer that has progressed despite multiple lines of treatment, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biweekly Combination for HER2-Positive Metastatic Breast CancerBiweekly Combination for HER2-Positive Metastatic Breast Cancer
Will this relatively tolerable combination of big-guns give something more to patients with advanced breast cancer? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

False Negative Results Found in Prognostic Testing for Breast Cancer
A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the U.S. and internationally. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - June 20, 2014 Category: Hospital Management Authors: Donna Dubuc Tags: Press Release Research breast cancer HER2 Norris Cotton Cancer Center Peter Kaufman Source Type: news

New research could provide key to overcoming resistance to HER2 targeted cancer treatments
(Trinity College Dublin) Scientists from Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments. The findings have just been published in leading international, peer reviewed journal: Cancer Research, the most frequently cited cancer journal in the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2014 Category: Global & Universal Source Type: news

Breast Cancer Therapeutics Market Worth $13.1 billion by 2020 Says a...
ReportsnReports.com adds latest report on “Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs” to its...(PRWeb June 07, 2014)Read the full story at http://www.prweb.com/releases/breast-cancer-therapeutic/market-2020-forecasts/prweb11922634.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 8, 2014 Category: Pharmaceuticals Source Type: news

Kadmon initiates Phase Ib/IIa trial of KD019 and Trastuzumab to treat HER2+ breast cancer
US-based Kadmon has started a Phase Ib/IIa trial of KD019, an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in combination with trastuzumab (Herceptin) to treat HER2+ breast cancer metastasized to the brain. (Source: Drug Development Technology)
Source: Drug Development Technology - June 6, 2014 Category: Pharmaceuticals Source Type: news

Angiochem beings Phase II trial of new peptide drug candidate to treat HER2+ breast cancer
Canadian biotechnology firm Angiochem has started a Phase II clinical trial of ANG1005, a novel paclitaxel-peptide drug conjugate, for the treatment of patients with HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 3, 2014 Category: Pharmaceuticals Source Type: news

Certain Breast Cancer Patients May Need Little Treatment After Tumor Removal
Study might provide an option to women with very small HER2-positive tumors Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Medicines, Women's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 2, 2014 Category: Consumer Health News Source Type: news

Study finds risk of recurrence low in smallest HER2+ breast cancer tumors
(Kaiser Permanente) Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2014 Category: Cancer & Oncology Source Type: news

Certain Breast Cancer Patients May Need Little Treatment After Tumor Removal
Study might provide an option to women with very small HER2-positive tumors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 2, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, News, Source Type: news

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab as adjuvant treatment for HER2 positive early breast cancer (Source: GSK news)
Source: GSK news - June 1, 2014 Category: Pharmaceuticals Source Type: news

ALTTO test of dual HER2 blockade finds single agent remains the gold standard
(Mayo Clinic) In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib did not add benefit to the standard trastuzumab adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2014 Category: Global & Universal Source Type: news

ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard
http://www.youtube.com/watch?v=PAyvFbGlWKY&feature=youtu.be Journalists: Broadcast soundbites with Dr. Perez are available in the downloads. CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 1, 2014 Category: Databases & Libraries Source Type: news

Team validates potentially powerful new way to treat HER2-positive breast cancer
(Cold Spring Harbor Laboratory) A CSHL-led research team reports that it has found a means of inhibiting a protein called PTP1B, whose expression is upregulated in HER2-positive breast cancer. They show that PTP1B plays a critical role in the development of tumors in which HER2 signaling is aberrant. Therefore, PTP1B may be a therapeutic target via which to treat the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 21, 2014 Category: Cancer & Oncology Source Type: news

How Does HER2 Status Affect Diagnosis and...
HER2, which is also called HER2/neu, and HER-2, is the acronym for human epidermal growth factor receptor 2. Knowing your HER2 status is an important part of your diagnosis. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - May 19, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Team validates potentially powerful new way to treat HER2-positive breast cancer
(Cold Spring Harbor Laboratory) Scientists at Cold Spring Harbor Laboratory today reported a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer called HER2-positive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2014 Category: Cancer & Oncology Source Type: news

Protein's role revealed in preventing heart muscle growth leading to heart failure
For the first time the protein Erbin has been shown to be an important brake that helps prevent pathological cardiac hypertrophy. Researchers showed that damage to this protein leads to excess growth of heart muscle, a decrease in function, and severe pathological growth of heart muscle. Their research has implications for breast cancer treatment, as Erbin interacts with the receptor Her2/ErBb2, which is overexpressed in approximately 30 percent of breast cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2014 Category: Science Source Type: news

Revealed:Protein's role in preventing heart muscle growth leading to heart failure
(The Hebrew University of Jerusalem) Hebrew University Faculty of Medicine researchers showed for the first time that the protein Erbin is an important brake that helps prevent pathological cardiac hypertrophy. They showed that damage to this protein leads to excess growth of heart muscle, a decrease in function, and severe pathological growth of heart muscle. Their research has implications for breast cancer treatment, as Erbin interacts with the receptor Her2/ErBb2, which is overexpressed in approximately 30 percent of breast cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 11, 2014 Category: Biology Source Type: news

New ASCO Guidelines Address HER2-Positive Breast CancerNew ASCO Guidelines Address HER2-Positive Breast Cancer
New ASCO guidelines recommend HER2-targeted therapy for most patients with HER2-positive advanced breast cancer, using trastuzumab, pertuzumab, and taxane for first-line treatment. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 8, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO Issues New Breast Cancer Tx Guidelines (CME/CE)
(MedPage Today) -- The American Society of Clinical Oncology has released two new sets of clinical practice guidelines for the treatment of women with advanced HER2-positive breast cancer. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 7, 2014 Category: American Health Source Type: news

ASCO Offers Guidance on Managing HER2-Positive Breast Cancer (FREE)
By Kelly Young The American Society of Clinical Oncology has published new recommendations for treating women with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. In addition, the group offers separate guidelines for treating brain … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 6, 2014 Category: Primary Care Source Type: news

Experts Issue Treatment Guidelines for Aggressive Form of Breast Cancer
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 5, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, News, Source Type: news

Experts Issue Treatment Guidelines for Aggressive Form of Breast Cancer
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy, Women's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 5, 2014 Category: Consumer Health News Source Type: news

Experts Issue Treatment Guidelines for Aggressive Form of Breast Cancer
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - May 5, 2014 Category: Cancer & Oncology Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Novel Drug 'Graduates' in Breast Ca Trial (CME/CE)
SAN DIEGO (MedPage Today) -- A targeted therapy for breast cancer "graduated" to phase III eligibility for patients with HER2-positive/hormone receptor-negative disease, data from an ongoing trial showed. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 11, 2014 Category: American Health Source Type: news

Eisai begins Phase III breast cancer study
US subsidiary of Japan-based Eisai has initiated a large, randomised Phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate injection to standard weekly paclitaxel as a first or second- line treatment for HER2-negative … (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2014 Category: Pharmaceuticals Source Type: news

Triple Negative Breast Cancer - Description,...
Triple negative breast cancer cells have no receptors for estrogen, progesterone, or HER2 protein. This type of breast cancer tends to be aggressive and survival rates are lower than average. Learn who is more at risk, and how triple negative breast cancer (TNBC) is treated. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 28, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Oncothyreon and Array begin Phase Ib breast cancer combination therapy study
Oncothyreon and Array BioPharma have started a Phase Ib study of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 24, 2014 Category: Pharmaceuticals Source Type: news

Natural compound attacks HER2 positive breast cancer cells
(Duke University Medical Center) A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2014 Category: Cancer & Oncology Source Type: news

Hot Topics: High Marks for Anti-HER2 Agents
(MedPage Today) -- Asked what works and what doesn't in breast cancer, four leaders in the field linked improved survival to adjuvant therapy and anti-HER2 agents, but all four said metastatic breast cancer remains a frustrating, incurable disease. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 10, 2014 Category: Geriatrics Source Type: news